Day: September 28, 2022

SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against Multiple COVID-19 Variants Including Omicron

SAB’s fully-human polyclonal antibody platform maintains its efficacy against multiple variants of several highly mutating virusesSIOUX FALLS, S.D., Sept. 28,...

error: Content is protected !!